ATED Therapeutics

Company Overview

Snapshot

Founded in March 2022, ATED Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on the development of diagnostics and therapeutics for central nervous system diseases.

Business overview

ATED Therapeutics is a Health Tech & Life Sciences company developing diagnostics and therapeutics for Parkinson’s disease and other central nervous system diseases. Its core product is an investigational transfer RNA fragment blood test designed to detect Parkinson’s earlier, monitor disease progression, and quantify response to deep brain stimulation. The company also develops two disease-modifying Parkinson’s drug candidates, serving the B2G and B2B markets within the Medical Devices and Diagnostics Devices sectors.

Company Intelligence Q&A

What is ATED Therapeutics' primary focus?

ATED Therapeutics is primarily focused on developing diagnostics and therapeutics for Parkinson’s disease and other central nervous system diseases.

What is the company's lead product?

The company's lead product is an investigational transfer RNA fragment blood test, intended to aid in earlier detection of Parkinson’s, monitor disease progression, and measure the effectiveness of deep brain stimulation.

What stage of development are ATED Therapeutics' drug candidates in?

ATED Therapeutics is developing two disease-modifying Parkinson’s drug candidates, which are currently in the R&D product stage.

When was ATED Therapeutics founded?

ATED Therapeutics was founded in March 2022.

In which sectors does ATED Therapeutics operate?

ATED Therapeutics operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Diagnostics Devices.